Publications found:
37,047
Sort by:
The Top 10 Pharma Companies in 2017
US$ 595.00
... extensive analysis from experts in many fields to predict the top 10 Pharma companies in 2017. To stay ahead of your competition, you need to have the ... fingertips. Download this powerful report today. Each of the top 10 pharma companies for 2017 has its own report, providing an overall sales ... for the ten pharma companies that are expected to lead the market in 2017 Analyst consensus sales forecasts for each company’s top five ...
February 2013
223 pages
The World Market for Implantable and Needle-Free Drug Delivery Systems
US$ 2,995.00
This report, The World Market for Implantable and Needle-Free Drug Delivery details the types of drug delivery systems and ... Drug Delivery Systems by Pharmaceutical and Drug Delivery Component Selected Suppliers of Implantable/Injectable Drug Delivery Technology Cost per Million Injections by Injector ...
February 2013
120 pages
Research Report on China’s Anti-Prostatic Hyperplasia (PH) Drug Market, 2013-2017
US$ 1,800.00
Benign prostatic hyperplasia (BPH) is a common disease among middle-aged and elderly men, with an increasing morbidity as the rise in ages. Its invasion ... patent drug manufacturers. Meanwhile, it is also a huge market. Therefore, the prospect of China’s anti-PH drug market is very bright. The annual growth rate ...
February 2013
40 pages
Antithrombotic Drugs: World Market 2013-2023
US$ 2,635.00
... What prospects for leading countries? Developments worldwide will influence the market, especially rising demand in emerging countries - e.g. Brazil and China. Our ... possibilities, helping you stay ahead. Nine ways Antithrombotic Drugs: World Market 2013-2023 helps To sum up, our investigation gives you ...
February 2013
119 pages
Pharma and the mHealth Revolution - Engaging with Mobile-Enabled Physicians and HCPs
US$ 595.00
... and mHealth developers themselves. Whether your company is looking to expand into mHealth apps or seeking sound advice on a way forward, Pharma and the mHealth Revolution - engaging ... from pharma in developing mHealth apps for healthcare providers Detailed insight into five major pharma mHealth projects Methodologies for determining the platforms on which mHealth ...
January 2013
83 pages
ISIS Pharma - Picture Beyond KYNAMRO - Targeting Other Niche Indications
US$ 140.00
... test that all antisense/ RNAi focused companies have to pass. ISIS has a robust cash position, valuable IP assets, and success of a few ... in the current pipeline could accelerate the transformation from a discovery to a pharma company and help it to grow beyond KYNAMRO.
January 2013
7 pages
IVD Procedure Volume and Pricing Analysis
US$ 3,995.00
... categories., Global procedure volume estimates are provided for the historic 2012 period and forecasts are provided through 2017. Price estimates are ... growth through the foreseeable future. Which company is performing what share of IVD procedures? This unique business planning tool answers this question, ...
January 2013
210 pages
VERTEX PHARMA - Faltering Pipeline and Sales
US$ 140.00
Vertex Pharma (VRTX) 4Q12/FY12 earnings and FY13 guidance (total revenue: ... is banking on success of its Cystic Fibrosis (CF) drugs in the pipeline for resurrection. VRTX endeavors could be too late in competing from ... read our report released on 31st January, 2013 on Vertex titled “Faltering Pipeline and Sales”
January 2013
4 pages
Research Report on China’s Anti-Alzheimer’s Disease (AD) Drug Market, 2013-2017
US$ 2,800.00
... the end of 2011, people aged 60 and above reached 185 million in China, accounting for 13.7% of the population, with an increase of 0.47 percentage point compared ... market development also accelerates. Although the overall market size of China's anti-AD drug market is relatively small, the growth rate is always ...
January 2013
40 pages
SUNPHARMA - Acquisitions to drive the next Growth Wave
US$ 140.00
... this will take time. Leveraging Balance sheet for Acquisition Consolidation of recent acquisitions (URL and DUSA) as well as management’s quest for new ... in US. Management has commented that Sun Pharma will continue to seek acquisitions in US (focus on Derma) and other emerging markets with small to medium ...
January 2013
7 pages
Pharma Clinical Trial Services: World Market 2013-2023
US$ 2,400.00
... will increase its revenues from 2013 to 2023, achieving strong growth. Clinical research organisations (CROs) and their clients will benefit. The ... you the technological and commercial possibilities. Eight ways Pharma Clinical Trial Services: World Market 2013-2023 helps To sum up, our investigation ...
January 2013
189 pages
Food Safety Diagnostics, The World Market
US$ 2,500.00
... unprecedented in an age of mass media, consumer alert systems and industrialized food production that together have led to high publicized outbreaks and food ... to pathogenic microbes Unlike other studies on the market, Food Safety Diagnostics, The World Market does not limit analysis to pathogens alone. ...
January 2013
140 pages
Vaccine Manufacturing Technology and Services: World Market 2013-2023
US$ 2,400.00
... revenues to 2023. It explains trends, opportunities and prospects for those technologies.а Our study lets you assess sales data at overall world ... and commercial possibilities. Eight ways Vaccine Manufacturing Technology and Services: World Market 2013-2023 helps In particular, then, our investigation ...
January 2013
194 pages
Indonesia Pharmaceuticals Industry Report - H2, 2012
US$ 475.00
... Farma Tbk, PT Merck Tbk, and PT Kimia Farma Tbk. Key Points: Indonesia’s pharmaceutical market is projected to grow at a CAGR of 10.8% over the next five ... reaching USD 12.2bn by 2017, and will rank as the sixth largest pharmaceutical market in the Asia-Pacific region. According to industry estimates, drug ...
January 2013
30 pages
The U.S. Market for Rx to OTC Switches, 6th Edition
US$ 3,995.00
... product areas contribute to the growth and development of the OTC market; however, new product development and additional regulatory review and ... label manufacturers. Competition will likely continue to be moderate in the OTC market, especially with the patent expiration of key products nearing. Consolidation ...
January 2013
290 pages
China Insulin Industry Report, 2012-2015
US$ 1,800.00
... analog market in 2011. In April 2012, the insulin phase Ⅲ project of the company held the groundbreaking ceremony. Once the project is put ... . The report highlights the followings: Global insulin industry: development, supply & demand, product R&D, competition pattern, development trend, etc. China insulin ...
January 2013
70 pages
Parkinson's Disease: World Drug Market 2013-2023
US$ 2,400.00
... Pain treatment Nicotinic receptor targeting. Also, our work covers the disease modification field, including: Possible neuroprotectants (including Azilect) Biomarkers GDNF ... for those CNS treatments. Eight main ways Parkinson's Disease: World Drug Market 2013-2023 helps you In particular, then, our ...
January 2013
161 pages
Big Data in Pharma Marketing
US$ 595.00
... on big data and how to work with it. Key Report Features A background to big data A summary of big data sources for pharma and biotech Uses for big data in pharma and biotech marketing Lessons from other industries Challenges facing those wanting to use big data ...
December 2012
76 pages
Global Pharmaceutical & Biotechnology Outlook 2013: Global Pharma
US$ 2,500.00
... Value added innovation) versus regulatory pressures to contain costs. Global Biopharmaceutical Outlook 2013-Large Cap Pharma, released by MP Advisors provides ... Emerging Markets and their importance in Growth of Large Cap Pharma 6. Global Pharma -Drugs Losing Patent Protection By 2017 7. Impact of patent ...
December 2012
131 pages
2013 Drugs of Abuse Testing Market: US, Europe, Japan
US$ 6,000.00
... from Venture Planning Group contains 311 pages and 61 tables. 'Drugs of Abuse Testing Market: US, Europe, Japan' is a unique study designed to help current ... start resembling commodity markets, where product positioning and cost per test are more critical than underlying technology. This evolving marketplace ...
December 2012
311 pages
Research Report on China's Antidepressant Market, 2013-2017
US$ 2,800.00
... , with the increasing recognition rate of doctors for depression and people's changes in treatment concepts, it is expected that the future potential of China's antidepressant market is fairly great. It is predicted that in coming years, the annual growth rate of market size of China's antidepressants in ...
December 2012
50 pages
Research Report on China's Antifungal Drug Market, 2013-2017
US$ 2,800.00
... of fungi increasingly enhances, so it indicates a sharply rising trend for the clinical application of antifungal drugs. It is expected that in coming years, the annual growth rate of market size of China's antifungal drugs will be over 20%. As for manufacturers, there are many opportunities. ...
December 2012
50 pages
Research Report on China's Diabetes Drug Market, 2013-2017
US$ 2,800.00
... aged above 20 has reached over 9.7%, and the morbidity rate of pre-diabetes (impaired fasting glucose and impaired glucose tolerance) has reached ... the market positions of insulin preparations and Acarbose. The market size of China's diabetes drugs is expected to maintain an annual growth rate of over 18% from ...
December 2012
50 pages
2013 U.S. Pharmacies & Drug Stores Industry-Product & Retail
US$ 199.00
The 2013 U.S. Pharmacies & Drug Stores Industry-Product & Retail report features 2013 current and 2014 forecast estimates on the sales of 61 product lines. The report also includes industry definition, 5-year historical trends on product lines sales. Product lines include ...
December 2012
123 pages
Research Report on China's Antithrombotic Drug Market, 2013-2017
US$ 2,400.00
... , the morbidity and mortality rates of cardiac-cerebral thrombotic diseases in China are higher than that in some developed countries. In addition, patients ... aggregation drugs and thrombolytic drugs. The overall market size of China's antithrombotic drugs is small, but it rapidly grows in recent years. The ...
December 2012
40 pages
Competitor Analysis: Herpes Virus Vaccines and Therapeutics
US$ 396.00
... infect humans. HSV-1 and HSV-2 cause the viral disease herpes simplex which can be categorized into one of several distinct disorders ... . In addition, the report lists company-specific R&D pipelines of Herpes Virus Vaccines & Therapeutics. Competitor projects are listed in a tabular format providing information ...
December 2012
56 pages
Indian Vaccine Industry: Trends & Opportunities (2012-2017)
US$ 800.00
... Indian Vaccine Industry: Trends and Opportunities (2012-2017) offers in-depth study of the global as well as the Indian vaccine industry with detailed discussion on the major segments of the vaccine industry ...
November 2012
62 pages
Drug Discovery Outsourcing: World Market 2013-2023
US$ 2,400.00
... prospects in leading regions and countries? Developments worldwide will influence the market, especially rising demand in emerging countries - China, India and others. ... shows you the commercial possibilities. Seven ways Drug Discovery Outsourcing: World Market 2013-2023 helps you In particular, then, our ...
November 2012
157 pages
Research Report on China's Hypolipidemic Drug Market, 2012-2013
US$ 2,400.00
... , the overall morbidity rate of dyslipidemia groups aged 18 and above is over 20% in China, and total patients are over 200 million nationwide. Blood ... , thus occupying a most advantageous position clinically. The overall performance of China's hypolipidemic drugs in the drug market is better than that of the ...
November 2012
55 pages
SUN PHARMA – Outperform, Balance Sheet Leveraging At Play
US$ 140.00
... complex generics to drive growth. In other words, balance sheet would remain the biggest growth driver, both for ... generics are dwindling. DUSA acquisition looks very attractive for Sun Pharma due to (1) DUSA is acquired at a trailing EV / Operating ... of Rs.795 and reiterate our Outperform rating on the stock.
November 2012
7 pages
Generic Drugs: World Market 2013-2023
US$ 2,400.00
... 2012 onwards: US, European and Japanese regulations Authorised, branded and other generics, including modified products Patent expiries and business strategies, including ... . You see how revenues can increase. Nine ways Generic Drugs: World Market 2013-2023 benefits you To sum up, our report gives you ...
November 2012
149 pages
World Pharmaceutical Contract Sales Market 2013-2023
US$ 2,401.00
... for service providers and clients. Eight ways World Pharmaceutical Contract Sales Market 2013-2023 benefits you To sum up, our report ... Opinions on the sector - discover views, including a research interview Coverage of market access and rising power of healthcare payers Investigation of competition and ...
November 2012
160 pages
Macular Degeneration (AMD) and Diabetic Retinopathy (DR): World Drug Market 2013-2023
US$ 2,401.00
... you discover its potential Where are treatments for macular degeneration (AMD) and diabetic retinopathy (DR) heading? Visiongain's updated report gives you ... will reach $6.25bn in 2015, our report forecasts. Ageing populations, diabetes and improving healthcare will increase sales of retinal drugs. In our ...
November 2012
153 pages
Biocon - Market Perform, Result Helped By Unsustainable Other Income
US$ 140.00
BIOCON - Market Perform, Result helped by unsustainable other income We reiterate our Market Perform rating on Biocon despite the Q2 FY13 result being higher than our estimates. ... values Syngene at ~11x EV/EBITDA – 16% higher than Biocon’s market valuation. We keep our estimate unchanged. We now rollover our ...
November 2012
7 pages
Social and Mobile Pharma - the State of the Digital Landscape
US$ 445.00
... consumers themselves are able to express concerns online. The influence of social media on pharma marketing is such that even the largest and most ... looks at leading-edge activities such as data mining, investigates the future of mobile access, outlines legislative and regulatory efforts worldwide and offers ...
October 2012
94 pages
US OTC Pharmaceutical Market Guide
US$ 197.00
... about the U.S. OTC Pharmaceutical Market’s competitive landscape, market share and industry segmentation in this research report. The United States is a large ... expected to grow at a moderate pace in the coming years, the U.S. OTC pharmaceuticals market is also looking for a decelerated growth till the year ...
October 2012
62 pages
Dr Reddy’S Lab - Market Perform, Great Result, Still Growth To Remain Modest
US$ 140.00
INDIA PHARMA Sub: DR REDDY’S LAB - Market Perform, Great Result, Still Growth to Remain Modest We reiterate our Market Perform rating on DRRD with an upward ... our estimate largely due to high growth in the US generics market business (17% Q-o-Q, constant currency). Other expenses remained lower sequentially ...
October 2012
8 pages
Gilead - Life Cycle Management For Hiv And Hcv Pipeline = Upside
US$ 140.00
... Subject: GILEAD – Life Cycle Management for HIV and HCV Pipeline = Upside Abstract 3Q12 earnings (Table 1) and revised upward revenue guidance validates Gilead’s (GILD ... , please read our report released on 1st Nov., 2012, titled, “Life Cycle Management for HIV and HCV Pipeline = Upside”. Report type – Deep ...
October 2012
7 pages
Alexion - Innovative Drugs For Orphan Diseases Focus = Stability!
US$ 140.00
Abstract Alexion (ALXN) products lack any near term competition ... products beyond Soliris. The fall in the stock price of Alexion (ALXN) despite robust 3Q12 earnings presents a long term buying ... read our report released on 31st September, 2012, titled, “ Innovative Drugs for Orphan Diseases Focus = Stability!”
October 2012
5 pages
Ipca - Outperform, Momentum Continues
US$ 140.00
INDIA PHARMA Subject: IPCA – Outperform, Momentum Continues We reiterate our Outperform on Ipca post its Q2 ... forward sales growth will be driven by (1) continuing growth in the anti malarial tender business to WHO ... to US likely from FY13 and (3) continuing growth from India and other branded markets. While we ...
October 2012
7 pages
Pharmaceutical Anti-counterfeiting Technologies: Market Analysis 2012-2022
US$ 2,401.00
... . You discover individual revenue forecasts to 2022 for these geographical markets: US Japan Germany, France, UK, Italy and Spain (EU5 countries, as a group) ... . Our work shows and explains. Seven ways Pharmaceutical Anti-counterfeiting Technologies: Market Analysis 2012-2022 helps you To sum up, our ...
October 2012
145 pages
Lupin - Market Perform, Margin Worry On Base Business
US$ 140.00
INDIA PHARMA Subject: LUPIN - Market Perform, Margin worry on base business Lupin’s Q2FY13 result was largely inline with our estimates, however, ... R&D expense. Ex-branded US generic sales declined sequentially despite Combivir gaining market share in Q2 FY13. All these indicate pressure on the US base ...
October 2012
7 pages
